Revolution Medicines RVMD
Revolution Medicines is a clinical-stage biotech developing therapies targeting the RAS(ON) pathway, a key mechanism in multiple cancers, with its lead candidate RASONQUE in development for solid tumors. Revolution Medicines, with 373% 12-month momentum and FDA breakthrough therapy designation for RASONQUE, has significant potential, but its valuation is demanding (FCF yield -1.62) and profitability is negative (ROE -79%), reflecting a clinical-stage biotech without revenue.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Revolution Medicines is a clinical-stage biotech developing therapies targeting the RAS(ON) pathway, a key mechanism in multiple cancers, with its lead candidate RASONQUE in development for solid tumors. Revolution Medicines, with 373% 12-month momentum and FDA breakthrough therapy designation for RASONQUE, has significant potential, but its valuation is demanding (FCF yield -1.62) and profitability is negative (ROE -79%), reflecting a clinical-stage biotech without revenue.
Score by category
| Category | Score |
|---|---|
| Financial health | 5.2 |
| Quality / Moat | 0.8 |
| Valuation | 0.5 |
| Dividend | 1.5 |
| Momentum | 9.8 |
| Risk & Context | 3.9 |
OVERALL SCORE: 2.8/10
Context and risks
The rise in 10-year yields (5.17%) affects loss-making biotechs like RVMD, whose value depends on distant future cash flows; however, the effect is already partially discounted in the model by duration. The interest rate exposure is moderate given its high-growth profile and lack of revenue.
News considered in the analysis
- Revolution Medicines (RVMD) Wins FDA Breakthrough Status For RASONQUE — La designación de terapia innovadora de la FDA acelera el desarrollo regulatorio de RASONQUE, un hito material que reduce el riesgo de desarrollo y mejora las perspectivas de aprobación.
- Revolution Medicines (RVMD) Deepens RAS(ON) Bet With Breakthrough PDAC Combo – But Is Risk Repricing? — La expansión de la combinación en cáncer de páncreas (PDAC) amplía el mercado potencial, pero el titular también señala un posible repricing del riesgo, lo que sugiere que parte de la noticia ya está en el precio.
- Is Revolution Medicines (RVMD) Cheap After Its FDA Breakthrough Therapy Win? — Artículo de análisis que discute la valoración tras el hito regulatorio; aporta perspectiva pero no información nueva material.
- Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines? — Comparativa genérica entre dos inversiones; sin información nueva sobre RVMD.
- Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold? — Noticia sobre un competidor sin impacto directo en RVMD.
Verdict: Hold or accumulate on dips, given the regulatory milestone and strong momentum, but with high volatility and development risk.
Main risk: The main risk is clinical or regulatory failure of RASONQUE, its lead candidate, which concentrates the company's value; a setback in trials could cause a sharp decline in the stock.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →